Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: wlheatmoon who wrote (587)	3/22/2000 10:50:00 PM
From: John Pitera	Read Replies (1) \| Respond to of 2850

Mike, the real closer on AHP is that they own 54% of IMNX which itself has a mkt cap of 22 billion today!!!! I agree AHP is value priced. Immunex develops biopharmaceutical products to treat cancer, autoimmune disorders, and infectious diseases. The company's primary approved products are Enbrel, for treating rheumatoid arthritis (FDA-approved in 1998, the drug has been the subject of controversy and has also shown promise to treat heart failure); Leukine, which is used to treat bone-marrow transplant patients; and Novantrone, which is used to treat acute non-lymphocytic leukemia and to ease pain associated with prostate cancer. Immunex is also developing drugs that treat asthma, leukemia, and certain cancers. Pharmaceutical research giant American Home Products, through its subsidiary American Cyanamid, owns 54% of Immunex. immunex.com Top Competitors: Amgen \| Bristol-Myers Squibb \| Merck